Coya Therapeutics, Inc. (COYA)

Coya Therapeutics, Inc. (COYA) Healthcare & Pipeline Overview

Coya Therapeutics, Inc. is a clinical-stage biotechnology company developing proprietary medicinal products to modulate regulatory T cells for neurodegenerative and autoimmune diseases. Headquartered in Houston, the company's pipeline includes Treg-enhancing biologics, exosomes, and cell therapies, with COYA 101 having completed Phase 2a for ALS.

What Is the Investment Thesis for COYA?

Coya Therapeutics, Inc. presents an investment thesis centered on its innovative approach to modulating regulatory T cells (Tregs) for neurodegenerative and autoimmune diseases, areas with significant unmet medical needs. The company's diverse pipeline, encompassing Treg-enhancing biologics, exosomes, and cell therapies, offers multiple shots on goal. COYA 101, having completed Phase 2a for Amyotrophic Lateral Sclerosis, represents the most advanced candidate, providing early clinical validation for its Treg modulation strategy. While the company currently operates with a negative profit margin of -266.1%, typical for clinical-stage biotechnology firms with substantial R&D investments, its reported gross margin of 99.8% suggests strong potential profitability if products reach commercialization. The relatively low Beta of 0.55 indicates lower volatility compared to the broader market. Future value drivers include successful progression of pipeline candidates through clinical trials, particularly IND filings for COYA 301 and COYA 302, and positive data readouts, which could significantly de-risk the pipeline and attract partnerships or further investment. The company's focus on proprietary products in high-need therapeutic areas positions it for potential long-term growth, contingent on clinical and regulatory success.

Based on FMP financials and quantitative analysis

COYA Key Highlights

• Market capitalization stands at $0.09 billion, reflecting its current valuation as a clinical-stage biotechnology company.
• Reported profit margin of -266.1% is characteristic of a development-stage company heavily investing in research and clinical trials.
• Achieved a gross margin of 99.8%, indicating strong potential profitability on product sales if candidates successfully reach commercialization.
• The company's Beta is 0.55, suggesting its stock price has historically exhibited lower volatility compared to the overall market.
• Operates with a lean team of 8 employees, focusing resources on specialized research and development activities.

Who Are COYA's Competitors?

COYA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are COYA's Key Strengths?

• Proprietary pipeline focused on regulatory T cell (Treg) modulation, a specialized area with therapeutic potential.
• Diverse therapeutic modalities, including biologics, exosomes, and cell therapy, offering multiple approaches to treatment.
• COYA 101 has completed Phase 2a clinical trials for ALS, providing early clinical validation.
• Targeting high-need neurodegenerative and autoimmune diseases with limited current treatment options.

What Are COYA's Weaknesses?

• Clinical-stage company with no commercialized products, leading to negative profit margins (-266.1%).
• Small employee base (8 employees) may limit the scope and speed of parallel development efforts.
• Significant capital requirements for ongoing research, development, and clinical trials.
• Reliance on successful clinical trial outcomes and regulatory approvals, which are inherently uncertain.

What Could Drive COYA Stock Higher?

• Initiation of Phase 2b or Phase 3 clinical trials for COYA 101 in Amyotrophic Lateral Sclerosis (ALS) following Phase 2a completion.
• Filing of Investigational New Drug (IND) applications for COYA 301 for Frontotemporal Dementia and COYA 302 for neurodegenerative and autoimmune diseases.
• Progression of COYA 201, an allogeneic Treg exosome product candidate, through preclinical development towards an IND application.
• Continued discovery-stage advancements for COYA 206, an antigen-directed Treg-derived exosome product candidate, identifying lead compounds.

What Are the Key Risks for COYA?

• Negative return on equity (-57.3%) — the business is not currently generating profit on shareholder capital.
• Clinical trial failures for any of its product candidates, including COYA 101, 301, or 302, which could halt development and significantly impact company valuation.
• Inability to secure necessary regulatory approvals from health authorities for its therapeutic products, leading to delays or denial of market access.
• Significant capital requirements for ongoing research and development, potentially necessitating future equity financing that could dilute existing shareholders.
• Intense competition within the biotechnology sector, particularly from companies developing treatments for neurodegenerative and autoimmune diseases, which could limit market share.
• Challenges in manufacturing and scaling up production of complex biologic and cell therapies, impacting commercial viability post-approval.

What Are the Growth Opportunities for COYA?

• Advancement of COYA 101 for Amyotrophic Lateral Sclerosis (ALS): The completion of Phase 2a clinical trials for COYA 101 positions it as the company's most advanced product candidate. ALS is a progressive neurodegenerative disease with limited treatment options and a high unmet medical need. Successful progression into later-stage clinical trials (Phase 2b/3) and eventual regulatory approval could tap into a significant market, potentially offering a novel therapeutic approach to slow disease progression or improve patient outcomes. The global ALS treatment market is projected to reach substantial valuations, offering a considerable opportunity for a breakthrough therapy.
• IND-enabling studies for COYA 301 in Frontotemporal Dementia (FTD): COYA 301, a Treg-enhancing biologic, is in IND-enabling studies for FTD, another severe neurodegenerative disorder with limited therapeutic options. Achieving an Investigational New Drug (IND) application and initiating clinical trials would mark a critical de-risking event and open access to a patient population in desperate need of effective treatments. The FTD market, while smaller than some other neurodegenerative diseases, still represents a significant opportunity for a first-in-class or best-in-class therapy.
• Development of COYA 302 for broad neurodegenerative and autoimmune diseases: COYA 302, a biologic combination designed to enhance Treg function while depleting T effector function and activated macrophages, targets a wide range of neurodegenerative and autoimmune conditions. This broad applicability could allow Coya Therapeutics to address multiple large markets with a single platform technology. Successful preclinical development and subsequent IND filing would unlock the potential to pursue various indications, significantly expanding the company's addressable market and revenue potential over a multi-year timeline.
• Preclinical advancement of COYA 201, an allogeneic Treg exosome product: COYA 201 is an allogeneic Treg exosome product candidate in the preclinical stage, targeting neurodegenerative, autoimmune, and metabolic diseases. Allogeneic therapies offer significant advantages in terms of manufacturing scalability and off-the-shelf availability compared to autologous approaches. Progressing this candidate through preclinical studies and towards an IND application could position Coya Therapeutics to enter the rapidly evolving exosome therapeutics market, which is projected for substantial growth due to its potential in various therapeutic areas.
• Discovery stage progress for COYA 206, an antigen-directed Treg-derived exosome: COYA 206 is an antigen-directed Treg-derived exosome product candidate in the discovery stage. This approach offers the potential for highly targeted immunomodulation, which could lead to therapies with improved efficacy and reduced off-target effects. Successful identification and validation of lead candidates, followed by preclinical development, could unlock a new frontier in precision medicine for autoimmune and inflammatory diseases, representing a long-term growth opportunity with the potential for high-value intellectual property.

What Opportunities Does COYA Have?

• Advancement of pipeline candidates into later-stage clinical trials and subsequent regulatory approvals.
• Potential for strategic partnerships or licensing agreements to accelerate development and commercialization.
• Expansion of Treg modulation into additional neurodegenerative, autoimmune, and metabolic indications.
• Addressing large, underserved markets with high unmet medical needs in target disease areas.

What Threats Does COYA Face?

• Risk of clinical trial failures, which could lead to significant delays or discontinuation of product candidates.
• Intense competition from larger pharmaceutical and biotechnology companies with greater resources.
• Challenges in obtaining regulatory approvals from health authorities.
• Need for continuous funding to support research and development activities, potentially leading to dilution for existing shareholders.

What Are COYA's Competitive Advantages?

• Proprietary product pipeline focused on modulating regulatory T cells (Tregs), a specialized area of immunology.
• Diverse therapeutic modalities including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
• Clinical validation with COYA 101 having completed Phase 2a trials for Amyotrophic Lateral Sclerosis (ALS).
• Targeting diseases with high unmet medical needs, potentially leading to significant market opportunities for novel therapies.
• Early-stage development of multiple candidates provides a broad intellectual property foundation in Treg-based therapeutics.

What Does COYA Do?

Coya Therapeutics, Inc., incorporated in 2020 and headquartered in Houston, Texas, operates as a clinical-stage biotechnology company dedicated to the development of proprietary medicinal products. The company's core focus is on modulating the function of regulatory T cells (Tregs), which play a critical role in immune system regulation. Coya Therapeutics' innovative product candidate pipeline is built upon diverse therapeutic modalities, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy, aiming to address significant unmet medical needs in complex diseases. A key asset in its pipeline is COYA 101, an autologous regulatory T-cell product candidate that has successfully completed a Phase 2a clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS). Beyond COYA 101, the company is actively advancing several other candidates. These include COYA 301, a Treg-enhancing biologic currently in IND-enabling studies for Frontotemporal Dementia, and COYA 302, a biologic combination designed for subcutaneous and/or intravenous administration to enhance Treg function while simultaneously depleting T effector function and activated macrophages, targeting a broad range of neurodegenerative and autoimmune diseases. Furthermore, Coya Therapeutics is exploring allogeneic approaches with COYA 201, an allogeneic Treg exosome product candidate in the preclinical stage for neurodegenerative, autoimmune, and metabolic diseases, and COYA 206, an antigen-directed Treg-derived exosome product candidate, which is in the discovery stage. This multi-pronged approach underscores the company's commitment to leveraging Treg biology across various therapeutic areas.

What Products and Services Does COYA Offer?

• Develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs).
• Focuses on treating neurodegenerative and autoimmune diseases, areas with high unmet medical needs.
• Utilizes three main therapeutic modalities: Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
• Has COYA 101, an autologous regulatory T-cell product, which has completed Phase 2a clinical trials for Amyotrophic Lateral Sclerosis (ALS).
• Advances COYA 301, a Treg-enhancing biologic, in IND-enabling studies for Frontotemporal Dementia.
• Develops COYA 302, a biologic combination intended to enhance Treg function and deplete T effector function for neurodegenerative and autoimmune diseases.
• Explores COYA 201, an allogeneic Treg exosome product, in preclinical stages for a range of diseases.
• Conducts discovery-stage research on COYA 206, an antigen-directed Treg-derived exosome product.

How Does COYA Make Money?

• Primarily focused on research and development of novel therapeutic candidates, typical for a clinical-stage biotechnology company.
• Future revenue generation is anticipated through the successful commercialization and sale of approved proprietary medicinal products.
• Potential for licensing agreements, collaborations, or partnerships with larger pharmaceutical companies for further development and commercialization of pipeline assets.
• Relies on capital raises through equity financing, grants, or strategic alliances to fund extensive preclinical and clinical trial activities.

What Industry Does COYA Operate In?

Coya Therapeutics operates within the highly specialized and capital-intensive biotechnology industry, specifically focusing on immunomodulation through regulatory T cells (Tregs). This niche positions the company within the broader healthcare sector, targeting neurodegenerative and autoimmune diseases that represent significant global health challenges with substantial unmet medical needs. The biotechnology landscape is characterized by intense research and development, lengthy clinical trial processes, and high regulatory hurdles. Coya's strategy of developing proprietary medicinal products based on Treg modulation distinguishes it within a competitive field, where many companies pursue various therapeutic approaches. The market for neurodegenerative and autoimmune disease treatments is vast and growing, driven by aging populations and increasing disease prevalence. Success in this industry is heavily reliant on scientific innovation, clinical efficacy, and the ability to navigate complex regulatory pathways, with significant potential for market disruption for novel, effective therapies.

Who Are COYA's Key Customers?

• Ultimately, patients suffering from neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia.
• Patients diagnosed with various autoimmune diseases that could benefit from Treg modulation.
• Healthcare providers and institutions that would prescribe and administer approved therapies.
• Potential pharmaceutical partners seeking to license or acquire innovative therapeutic candidates for their portfolios.

Company Profile

Coya Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Arun Swaminathan. COYA has traded publicly since 2022.

Coya Therapeutics, Inc. Financial Trajectory

Coya Therapeutics, Inc. (COYA) reported $251K in revenue for Q1 2026, a decline of 93.7% compared to the prior quarter. The company recorded a net loss of $7.2M, with diluted EPS of $-0.32. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, COYA averaged $-0.29 in diluted EPS.

How Coya Therapeutics, Inc. Is Valued

Coya Therapeutics, Inc. carries a market capitalization of $107.80M, placing it in the micro-cap category. Relative to its peer group, COYA's quantitative score of 32/100 is below the peer average of 76/100.

ROE -57%Key Financial Metrics

Return on equity for Coya Therapeutics, Inc. stands at -57.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -39.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -13.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 15.02 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -21.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

Coya Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 13.03 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Coya Therapeutics, Inc. revenue of about $2.4M for fiscal 2026, with EPS near $-1.36. The estimate reflects 5 contributing analysts.

COYA Financials

COYA Latest News

COYA Analyst Consensus

COYA MoonshotScore

Common Questions About COYA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources